PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. is a precision oncology company specializing in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate, PC14586, is a small molecule designed to correct the Y220C mutation in p53 protein and restore wild-type p53 function. The company also focuses on developing mutant p53 programs for various p53 hotspot mutations. By leveraging its innovative small molecule therapies, PMV Pharmaceuticals aims to generate revenue through the commercialization of its precision oncology treatments for patients with p53-mutated cancers.